Heart failure & cardiomyopathies
Pathophysiology and Clinical Use of Agents with Vasodilator Properties in Acute Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
Recommendations
As issued by the authors
No firm recommendation suggesting vasodilator treatment over usual care
Acute heart failure (AHF) trial design should consider phenotype diversity of AHF patients
New RCTs should focus on subgroups that may mechanistically benefit from vasodilators, possibly enrolling close to decompensation, e.g. in the ED
Original publication
Pathophysiology and Clinical Use of Agents with Vasodilator Properties in Acute Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. Published 4 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →